One of the four new bed bays that will be used for clinical trials. Photo: Nathan Schmidt.
THE second stage of the Canberra Hospital’s $22.4 million cancer ward refurbishment opened to the public today (April 21).
Located in the Canberra Region Cancer Centre, Ward 14B will feature 28 beds – up from the 26 previously provided – as well as a patient/family dining area and therapy gym space.
Along with a new design and consultation and treatment facilities, Health Minister Rachel Stephen-Smith says the redesign will enhance the holistic care provided to oncology patients.
The minister opened the ward yesterday, more than two years after the first phase, Ward 14A, was inaugurated.
Date Time
Improving care for cancer patients at Canberra Hospital
More Canberra Hospital cancer inpatients will receive treatment in completely refurbished surroundings following the opening of the second stage of the hospital’s cancer ward upgrades.
ACT Minister for Health Rachel Stephen-Smith opened Ward 14B today, providing an updated patient and family friendly ward for our oncology patients – part of our major program of infrastructure works across the Canberra Hospital campus.
“The refurbished ward adds to our modernised cancer precinct at Canberra Hospital, including the treatment and consultation spaces at the Canberra Region Cancer Centre” Minister Stephen‑Smith said.
“Our dedicated health care workers are looking forward to caring for their patients in a new environment that will make a patient’s stay in the ward as pleasant as possible under very difficult and life challenging circumstances.
International consortium to provide recommendations for understanding PRO data in cancer clinical trials
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
SISAQOL-IMI (Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials - IMI) will establish guidance on how to use patient-reported outcomes in cancer clinical trials so that they can be used in a methodologically sound way, analyzed in a statistically adequate manner, and intelligibly presented to ensure a high study quality and better comparability of results across clinical trials.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Breast cancer therapeutics market in the US represents itself as a paralleled contributor to the total pharmaceutical market in the country. The high mean value of the market is oftenly observed as of high interest by the researchers in the emerged market. The upside potential of the market is booming, with only very little down quirks. In addition to this, the country s outlook of the breast cancer drug use and spending for research and development is a must-watched parameter for the other emerging markets of the world.
The research report developed for the market includes all the latest predictions for the US breast cancer market, in addition to this including several areas of growth, research and development process and many more. The report involves the impact of the novel drug launches on the already available drugs as well as the driving forces for the available medicines. In addition to the comprehen
Press release content from Business Wire. The AP news staff was not involved in its creation.
United States Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insights 2026 - ResearchAndMarkets.com
January 22, 2021 GMT
DUBLIN (BUSINESS WIRE) Jan 22, 2021
Breast cancer therapeutics market in the US represents itself as a paralleled contributor to the total pharmaceutical market in the country. The high mean value of the market is oftenly observed as of high interest by the researchers in the emerged market. The upside potential of the market is booming, with only very little down quirks. In addition to this, the country’s outlook of the breast cancer drug use and spending for research and development is a must-watched parameter for the other emerging markets of the world.